Compare CRL & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | GKOS |
|---|---|---|
| Founded | 1947 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 10.9B |
| IPO Year | 1999 | 2015 |
| Metric | CRL | GKOS |
|---|---|---|
| Price | $297.71 | $180.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $198.27 | $126.92 |
| AVG Volume (30 Days) | ★ 923.3K | 907.6K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,857,601,000.00 | $507,442,000.00 |
| Revenue This Year | N/A | $23.32 |
| Revenue Next Year | $3.04 | $27.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 10.48 | ★ 32.33 |
| 52 Week Low | $144.26 | $73.16 |
| 52 Week High | $300.59 | $191.62 |
| Indicator | CRL | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 76.44 | 54.66 |
| Support Level | $149.72 | $175.04 |
| Resistance Level | N/A | $184.00 |
| Average True Range (ATR) | 9.71 | 6.19 |
| MACD | 0.64 | -1.60 |
| Stochastic Oscillator | 93.34 | 27.39 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.